These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33428488)

  • 1. Elbasvir and grazoprevir for the treatment of hepatitis C.
    Wang SJ; Huang CF; Yu ML
    Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1071-1081. PubMed ID: 33428488
    [No Abstract]   [Full Text] [Related]  

  • 2. Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.
    El Kassas M; Elbaz T; Abd El Latif Y; Esmat G
    Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1413-1421. PubMed ID: 27603877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
    Brown A; Hézode C; Zuckerman E; Foster GR; Zekry A; Roberts SK; Lahser F; Durkan C; Badshah C; Zhang B; Robertson M; Wahl J; Barr E; Haber B;
    J Viral Hepat; 2018 May; 25(5):457-464. PubMed ID: 29152828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
    Kumada H; Suzuki Y; Karino Y; Chayama K; Kawada N; Okanoue T; Itoh Y; Mochida S; Toyoda H; Yoshiji H; Takaki S; Yatsuzuka N; Yodoya E; Iwasa T; Fujimoto G; Robertson MN; Black S; Caro L; Wahl J
    J Gastroenterol; 2017 Apr; 52(4):520-533. PubMed ID: 27873094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.
    Gane E; Nahass R; Luketic V; Asante-Appiah E; Hwang P; Robertson M; Wahl J; Barr E; Haber B
    J Viral Hepat; 2017 Oct; 24(10):895-899. PubMed ID: 28470815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
    Toyoda H; Atsukawa M; Takaguchi K; Senoh T; Michitaka K; Hiraoka A; Fujioka S; Kondo C; Okubo T; Uojima H; Tada T; Yoneyama H; Watanabe T; Asano T; Ishikawa T; Tamai H; Abe H; Kato K; Tsuji K; Ogawa C; Shimada N; Iio E; Deguchi A; Itobayashi E; Mikami S; Moriya A; Okubo H; Tani J; Tsubota A; Tanaka Y; Masaki T; Iwakiri K; Kumada T
    J Gastroenterol; 2018 Dec; 53(12):1276-1284. PubMed ID: 29740665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study.
    Jacobson IM; Poordad F; Firpi-Morell R; Everson GT; Verna EC; Bhanja S; Hwang P; Caro L; Robertson M; Charles ED; Platt H
    Clin Transl Gastroenterol; 2019 Apr; 10(4):e00007. PubMed ID: 30939489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.
    Elbasha EH; Robertson MN; Nwankwo C
    Aliment Pharmacol Ther; 2017 Feb; 45(3):455-467. PubMed ID: 27910116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Men Who Have Sex With Men.
    Braun DL; Hampel B; Kouyos R; Nguyen H; Shah C; Flepp M; Stöckle M; Conen A; Béguelin C; Künzler-Heule P; Nicca D; Schmid P; Delaloye J; Rougemont M; Bernasconi E; Rauch A; Günthard HF; Böni J; Fehr JS;
    Clin Infect Dis; 2019 Feb; 68(4):569-576. PubMed ID: 30107485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials.
    Gane EJ; Pianko S; Roberts SK; Thompson AJ; Zeuzem S; Zuckerman E; Ben-Ari Z; Foster GR; Agarwal K; Laursen AL; Gerstoft J; Gao W; Huang HC; Fitzgerald B; Fernsler D; Li JJ; Grandhi A; Liu H; Su FH; Wan S; Zeng Z; Chen HL; Dutko FJ; Nguyen BT; Wahl J; Robertson MN; Barr E; Yeh WW; Plank RM; Butterton JR; Esteban R
    Lancet Gastroenterol Hepatol; 2017 Nov; 2(11):805-813. PubMed ID: 28802816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C.
    Karaoui LR; Mansour H; Chahine EB
    Am J Health Syst Pharm; 2017 Oct; 74(19):1533-1540. PubMed ID: 28947524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.
    Zarębska-Michaluk D; Jaroszewicz J; Buczyńska I; Simon K; Lorenc B; Tudrujek-Zdunek M; Tomasiewicz K; Sitko M; Garlicki A; Janczewska E; Dybowska D; Halota W; Pawłowska M; Pabjan P; Mazur W; Czauż-Andrzejuk A; Berak H; Horban A; Socha Ł; Klapaczyński J; Piekarska A; Blaszkowska M; Belica-Wdowik T; Dobracka B; Tronina O; Deroń Z; Białkowska-Warzecha J; Laurans Ł; Flisiak R
    J Gastroenterol Hepatol; 2020 Jul; 35(7):1238-1246. PubMed ID: 31734959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elbasvir/grazoprevir is effective and tolerable for the treatment of HCV GT1-infected patients: A real world multicenter observatory study in Taiwan.
    Cheng PN; Chen CY; Yu ML; Lin CC; Lin CY; Peng CY; Tseng KC; Lo CC; Tseng IH; Liu CJ
    J Microbiol Immunol Infect; 2021 Aug; 54(4):588-595. PubMed ID: 32499107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis.
    Zheng YX; Ma SJ; Xiong YH; Fan XG
    J Gastroenterol Hepatol; 2020 Sep; 35(9):1477-1487. PubMed ID: 32246857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection.
    Corman S; Elbasha EH; Michalopoulos SN; Nwankwo C
    Value Health; 2017 Sep; 20(8):1110-1120. PubMed ID: 28964443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C.
    Sulejmani N; Jafri SM; Gordon SC
    Expert Opin Drug Metab Toxicol; 2016; 12(3):353-61. PubMed ID: 26849059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
    Elbasha E; Greaves W; Roth D; Nwankwo C
    J Viral Hepat; 2017 Apr; 24(4):268-279. PubMed ID: 27966249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease.
    Ogawa E; Furusyo N; Azuma K; Nakamuta M; Nomura H; Dohmen K; Satoh T; Kawano A; Koyanagi T; Ooho A; Takahashi K; Kato M; Shimoda S; Kajiwara E; Hayashi J;
    Antiviral Res; 2018 Nov; 159():143-152. PubMed ID: 30300717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.
    Suda G; Kurosaki M; Itakura J; Izumi N; Uchida Y; Mochida S; Hasebe C; Abe M; Haga H; Ueno Y; Masakane I; Abe K; Takahashi A; Ohira H; Furuya K; Baba M; Yamamoto Y; Kobayashi T; Kawakami A; Kumagai K; Terasita K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    J Gastroenterol; 2019 Jan; 54(1):78-86. PubMed ID: 30019127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
    Komatsu TE; Boyd S; Sherwat A; Tracy L; Naeger LK; O'Rear JJ; Harrington PR
    Gastroenterology; 2017 Feb; 152(3):586-597. PubMed ID: 27773808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.